证券代码：600833 证券简称：第一医药 公告编号：临 2025-050 上海第一医药股份有限公司 二、规范运作管理，提升公司治理水平 公司严格按照《公司法》《证券法》《上海证券交易所股票上市规则》等法律法规、 规范性文件和《公司章程》规定，构建了以股东会、董事会及专门委员会和管理层为核 心主体的治理结构，形成了权力机构、决策机构、监督机构和管理层之间分工明确、权 责清晰、协调运作、相互制约的治理机制，构建了紧密衔接、高效协同的治理与管理架 构。 2024 年以来，公司根据监管政策变化及经营需求，修订《公司章程》《独立董事工 作细则》等多项内部制度，创新独立董事选任机制，荣获上海辖区独立董事制度改革"优 秀实践"案例，进一步夯实治理基础。同时，公司将董事会战略委员会变更为战略与 ESG 委员会，并完成监事会撤销流程，相应职责由董事会审计委员会承接，有效提升公司可 持续健康发展和管理运作水平。 未来，公司将持续提升治理水平，紧密关注证监会、交易所最新监管政策，及时修 订内部管理制度以适配监管要求与公司发展阶段；组建覆盖医保合规、药品追溯等领域 的合规管理标准化体系并定期开展风险排查；明确独立董事履职定位与保障 ...

第十一届董事会第六次（临时）会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 重要内容提示：本次董事会不存在否决议案，没有董事投反对/弃权票。 上海第一医药股份有限公司（以下简称"公司"）第十一届董事会第六次（临时） 会议于 2025 年 11 月 16 日以邮件方式通知，于 2025 年 11 月 21 日以通讯方式召开。本 次会议由董事长张海波先生召集并主持。本次会议应参加表决董事为 9 名，委托表决 0 名，实际参加表决董事 9 名。会议的召开符合有关法律、行政法规、部门规章、规范性 文件和《公司章程》的规定，会议形成的决议合法、有效。 根据会议议程，本次会议审议通过以下事项： 一、公司《关于制定 2025 年"提质增效重回报"行动方案的议案》 证券代码：600833 证券简称：第一医药 公告编号：临 2025-049 上海第一医药股份有限公司 1 三、公司《关于修订<违规经营投资责任追究实施办法>的议案》 结合公司实际情况及组织架构的调整，根据《公司章程》具体要求，修订《违规经 营投资责任追究实施办法》部 ...

Core Viewpoint - First Pharmaceutical (SH 600833) held a temporary board meeting on November 21, 2025, to discuss the "Quality Improvement and Efficiency Recovery" action plan for 2025 [1] Financial Performance - For the first half of 2025, First Pharmaceutical's revenue composition was as follows: retail pharmacy accounted for 61.63%, wholesale pharmacy for 35.49%, and other businesses for 2.88% [1] - As of the report date, First Pharmaceutical's market capitalization was 2.9 billion yuan [1]

Core Viewpoint - The company reported that as of the end of the third quarter of 2025, the total number of common stock shareholders is 25,293 [1] Summary by Category - **Company Information** - The total number of common stock shareholders for the company is 25,293 as of the end of the third quarter of 2025 [1]

Core Insights - The pharmaceutical commercial sector experienced a rise of 1.05% on November 14, with significant gains led by the stock of Jiyu Pingmin, which surged by 20.03% [1] - The Shanghai Composite Index closed at 3990.49, down 0.97%, while the Shenzhen Component Index closed at 13216.03, down 1.93% [1] Stock Performance - Jiyu Pingmin (301017) closed at 16.66 with a gain of 20.03%, trading volume of 141,800 shares and a transaction value of 227 million [1] - Renmin Tongtai (600829) and Kaikai Industry (600272) also saw notable increases of 10.04% and 10.03%, respectively [1] - The pharmaceutical sector's stocks showed a mixed performance, with some stocks like Jianfa Zhixin (301584) and Runda Medical (603108) declining by 3.33% and 1.59% respectively [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 497 million from institutional investors, while retail investors contributed a net inflow of 590 million [2][3] - The main stocks experiencing significant net inflows from retail investors included Jiyu Pingmin and Kaikai Industry, while institutional investors showed a preference for stocks like Kaikai Industry [3]

Core Points - The company, Shanghai First Pharmaceutical Co., Ltd., has reported its third-quarter operational data for 2025, ensuring the accuracy and completeness of the information provided [8]. Financial Data - The financial statements for the third quarter are unaudited, and the report covers the period from the beginning to the end of the quarter [3][7]. - The company has not recognized any non-recurring gains or losses during the reporting period [4]. Store Operations - As of September 30, 2025, the company operates 214 stores, including 48 franchise stores, with a total operating area of 21,768.9 square meters [8]. - In the first nine months of 2025, the company added 6 new stores, with a total of 22 new openings (9 direct-operated and 13 franchise), while closing 16 stores [8]. - Among the 166 direct-operated stores, 129 have obtained the qualification as "medical insurance designated retail pharmacies," representing 77.71% of the total direct-operated stores, an increase of 10.05 percentage points compared to the end of the previous year [8].

Core Insights - The company reported a revenue of 542,480,778.50 yuan for the third quarter of 2025, representing a year-on-year growth of 14.04% [1] - The net profit attributable to shareholders of the listed company was 39,245,693.69 yuan, showing a significant year-on-year increase of 123.80% [1]

证券代码：600833 证券简称：第一医药 公告编号：临 2025-048 上海第一医药股份有限公司 一、报告期门店变动情况 2025 年第三季度经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海第一医药股份有限公司（以下简称"公司"）根据《上海证券交易所上市公司自 律监管指引第 3 号——行业信息披露（第四号——零售）》的相关要求，现将公司 2025 年第三季度主要经营数据披露如下： 二、报告期末主要经营数据 | 分地区 | 营业收入（元） | 营业收入比 同期增减(%) | 营业成本（元） | 营业成本比 同期增减(%) | 毛利率 (%) | 毛利率比同期增减 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 上海 地区 | 1,498,084,623.02 | 12.47 | 1,283,908,641.61 | 13.14 | 14.30 | 减少 0.51 | 个百分点 | 特此公告。 上海第一医药股份有限公司董事会 2025 年 10 ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥542,480,778.50, representing a year-on-year increase of 14.04%[3] - The total profit for the quarter was ¥52,374,952.68, a significant increase of 124.02% compared to the same period last year[3] - Net profit attributable to shareholders was ¥39,245,693.69, up 123.80% year-on-year[3] - The basic earnings per share for the quarter was ¥0.1759, reflecting a 123.79% increase compared to the previous year[3] - The net profit attributable to shareholders for the year-to-date was ¥53,269,885.92, down 63.84% compared to the previous year[3] - The net profit for the first three quarters of 2025 is CNY 54,020,386.58, a decrease from CNY 147,358,092.70 in the same period of 2024, representing a decline of approximately 63.4%[18] - Operating profit for the first three quarters of 2025 is CNY 63,455,424.94, down from CNY 153,647,524.75 in 2024, indicating a decrease of about 58.7%[18] - The total comprehensive income for the first three quarters of 2025 is CNY 74,974,927.96, down from CNY 146,660,041.96 in 2024, a decrease of approximately 48.9%[18] - Basic and diluted earnings per share for the first three quarters of 2025 are both CNY 0.2388, down from CNY 0.6604 in 2024, representing a decline of about 63.8%[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,030,693,993.01, an increase of 2.56% from the end of the previous year[4] - Total assets as of September 30, 2025, amounted to CNY 2,030,693,993.01, up from CNY 1,980,057,333.84 at the end of 2024, an increase of 2.5%[14] - Total liabilities increased slightly to CNY 860,399,830.63 from CNY 835,659,103.08, reflecting a growth of 2.9%[13] - Shareholders' equity rose to CNY 1,170,294,162.38, compared to CNY 1,144,398,230.76 in 2024, an increase of 2.3%[14] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥24,541,621.52[3] - Cash flow from operating activities for the first three quarters of 2025 is CNY 24,541,621.52, compared to a negative cash flow of CNY 51,595,472.56 in the same period of 2024, showing a significant improvement[20] - The cash flow from investing activities for the first three quarters of 2025 is CNY 6,852,987.70, compared to CNY 4,793,074.33 in 2024, reflecting an increase of approximately 43.0%[21] - The total cash outflow from financing activities for the first three quarters of 2025 is CNY 190,377,229.39, compared to CNY 218,473,721.73 in 2024, indicating a decrease of approximately 12.9%[21] - The cash and cash equivalents at the end of the period for 2025 is CNY 368,615,925.25, up from CNY 277,907,854.36 in 2024, indicating a growth of about 32.6%[21] Operational Metrics - Total operating revenue for the first three quarters of 2025 reached CNY 1,539,077,117.96, an increase of 12.4% compared to CNY 1,368,880,300.43 in the same period of 2024[17] - Total operating costs for the first three quarters of 2025 were CNY 1,536,044,900.73, up from CNY 1,367,296,395.88 in 2024, reflecting a growth of 12.4%[17] - Operating profit margin improved, with operating costs as a percentage of revenue decreasing from 100.1% in 2024 to 99.9% in 2025[17] - The company reported a net profit for the first three quarters of 2025, with a profit margin improvement due to cost management strategies implemented during the period[17] Inventory and Receivables - Inventory increased significantly to CNY 406,629,703.58, compared to CNY 336,323,956.50 in 2024, marking a rise of 20.9%[12] - Accounts receivable decreased to CNY 172,162,204.84 from CNY 189,373,266.78, a reduction of 9.4%[11] Other Information - The company received compensation for property expropriation, which significantly impacted the profit figures for the quarter[5] - The weighted average return on equity decreased by 9.25 percentage points to 4.64% year-to-date[3] - The company reported non-recurring gains and losses totaling ¥38,619,257.70 for the quarter[6] - The company has not executed any mergers or acquisitions during the reporting period[22]

Market Overview - The pharmaceutical commercial sector increased by 0.44% on October 23, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3922.41, up 0.22%, while the Shenzhen Component Index closed at 13025.45, also up 0.22% [1] Stock Performance - Jianfa Zhixin (301584) saw a significant rise of 20.00%, closing at 37.20 with a trading volume of 301,100 shares and a transaction value of 1.046 billion [1] - Other notable performers included: - Kaikai Industrial (600272) up 2.20% to 13.49 [1] - First Pharmaceutical (600833) up 1.97% to 14.01 [1] - Dazhenlin (603233) up 1.48% to 19.20 [1] - Yifeng Pharmacy (603939) up 1.31% to 25.44 [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 97.0483 million from institutional investors and 117 million from speculative funds, while retail investors saw a net inflow of 214 million [2] - The capital flow for key stocks showed: - Jianfa Zhixin had a net inflow of 1.22 billion from institutional investors, but a net outflow of 58.2871 million from speculative funds [3] - Kaikai Industrial had a net inflow of 15.4487 million from institutional investors, with a net outflow of 3.9622 million from speculative funds [3]